Stock Analiz

Lineage Cell Therapeutics, Inc. LCTX

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.91Market cap $231M
Open the interactive analysis →

Lineage Cell Therapeutics, Inc. (LCTX) is a healthcare company listed in the US with a market value of about $231M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of $2M, a net margin of 16.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 51% a year, a 5-year average ROIC of -39%.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $5M in 2014 to $15M in 2025, growth of about 9.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 36% over three years (dilution for shareholders). It spends 122% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S21.3
P/B3.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)53.2%
Revenue growth (5 yrs, per year)51.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-408.5%
ROIC (5-yr avg.)-39.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$11M$15M$9M$9M$15M$4M$2M$4M$5M$3M—
Net income$2M-$64M-$19M-$21M-$26M-$43M-$21M-$12M-$46M-$20M$34M
Free cash flow-$26M-$19M-$24M-$29M$646000-$24M-$20M-$32M-$31M-$32M-$45M
EPS (diluted)$-0.09$-0.28$-0.09$-0.12$-0.15$-0.26$-0.14$-0.08$-0.36$-170.00$340.00
Net margin16.2%-436.5%-195.9%-240.2%-178.7%-991.0%-1130.8%-333.1%-922.0%-577.7%—
ROIC—-72.1%-26.6%-34.4%-23.1%-40.9%-25.9%-21.0%-34.5%-18.9%-39.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $5.50, 501% above the current price; targets range from $3.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.09 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Lineage Cell Therapeutics pay a dividend?

Not currently.

Is Lineage Cell Therapeutics a good stock to buy?

We do not give buy or sell advice. Lineage Cell Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.